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Organometallic rhodium(III) and iridium(III)
cyclopentadienyl complexes with curcumin and
bisdemethoxycurcumin co-ligands†
Riccardo Pettinari,*a Fabio Marchetti,b Claudio Pettinari,a Francesca Condello,a
Agnese Petrini,a Rosario Scopelliti,c Tina Riedelc and Paul J. Dyson*c
A series of half-sandwich cyclopentadienyl rhodium(III) and iridium(III) complexes of the type [Cp*M(curc/
bdcurc)Cl] and [Cp*M(curc/bdcurc)(PTA)][SO3CF3], in which Cp* = pentamethylcyclopentadienyl, curcH
= curcumin and bdcurcH = bisdemethoxycurcumin as O^O-chelating ligands, and PTA = 1,3,5-triaza-7-
phosphaadamantane, is described. The X-ray crystal structures of three of the complexes, i.e. [Cp*Rh-
(curc)(PTA)][SO3CF3] (5), [Cp*Rh(bdcurc)(PTA)][SO3CF3] (6) and [Cp*Ir(bdcurc)(PTA)][SO3CF3] (8), conﬁrm
the expected “piano-stool” geometry. With the exception of 5, the complexes are stable under pseudo-
physiological conditions and are moderately cytotoxic to human ovarian carcinoma (A2780 and
A2780cisR) cells and also to non-tumorigenic human embryonic kidney (HEK293) cells, but lack the
cancer cell selectivity observed for related arene ruthenium(II) complexes.
Introduction
Curcumin is a naturally occurring polyphenol derived from the
rhizomes of turmeric (Curcuma longa).1 Curcumin (curcH) is
the major component of three curcuminoids that give turmeric
its characteristic yellow color. The minor curcuminoid com-
ponents are demethoxycurcumin (dcurcH) and bisdemethoxy-
curcumin (bdcurcH) in which one or both –OMe
functionalities at the outer phenol rings are removed.
Curcumin displays potent activity in vitro and in animal
studies, acting as an anti-proliferative, anti-metastatic and
antiangiogenic agent.2–5 Numerous studies have also explored
the antioxidant, anti-hepatotoxic, anti-hyperlipidemic, anti-
viral, and anti-Alzheimer’s disease eﬀects.6,7 Despite the prom-
ising biological eﬀects of curcumin at the preclinical and
clinical levels its therapeutic applications are, however,
restricted by poor solubility and rapid metabolism resulting in
very low bioavailability following oral administration.8 One
strategy used to improve the biological (drug-like) properties of
curcumin, which avoids covalently modifying the com-
pound,9,10 is to coordinate it to metal complexes.11–13
Ruthenium compounds have emerged, in recent years, as
promising alternatives to platinum drugs by displaying specific
activities against diﬀerent cancers and favourable toxicity and
clearance properties.14–21 Previously, we have demonstrated
that half-sandwich ruthenium-arene complexes with curcumin
and bisdemethoxycurcumin and an ancillary chloride ligand
show promising activity as anticancer agents.22,23 We have also
shown that the replacement of chloride with the 1,3,5-triaza-7-
phosphaadamantane ligand (PTA) led to the formation of
RAPTA-type complexes with superior solubility properties and
also superior cytotoxicities.24 It was found that the presence or
absence of peripheral methoxy groups in curcumin and the
diﬀerent arene rings do not strongly influence the biological
activity whereas the PTA ligand appears to significantly
improve the pharmacological properties of the curcumin-
modified arene ruthenium(II) complexes.
Rhodium and iridium complexes have been explored for
their anticancer properties with initial eﬀorts being focused
on Rh(I) and Ir(I) compounds with a square-planar geometry
similar to that of cisplatin.25,26 Recently, more stable cyclopenta-
dienyl Rh(III) and Ir(III) complexes, with higher structural
diversity and a higher coordination number (6 versus 4),27,28
have been shown to have highly potent anticancer activity.29–40
Based on the highly promising pharmacological properties
of the arene ruthenium(II) complexes incorporating curcumin
and bisdemethoxycurcumin co-ligands, combined with the
exciting developments on the anticancer properties of Rh(III)
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and Ir(III) organometallic compounds, we decided to integrate
these two areas and prepare and evaluate some pentamethyl-
cyclopentadienyl Rh(III) and Ir(III) compounds containing
curcumin-based ligands and, in some cases, PTA. It should be
noted that two curcumin complexes of Rh(III) and Ir(III) have
been reported,41 but structural data and biological studies
were not described.
Results and discussion
Synthesis
The rhodium(III) and iridium(III) pentamethylcyclopentadienyl
complexes (1–4) were prepared in high yield (78–93%) from
the reaction of the appropriate dimer, [Cp*MCl2]2, (M = Rh or
Ir, Cp* = η5-pentamethylcyclopentadienyl) with the appropriate
pro-ligand and KOH in methanol (Scheme 1). Analytical and
spectral data for 1 and 3 are in accordance with literature
data.41
Complexes 1–4 are air stable and soluble in acetone, aceto-
nitrile and DMSO and slightly soluble in alcohols. In addition,
the curcumin complexes, 1 and 3, are also soluble in chlori-
nated solvents. Such diﬀerent solubilities appear to be due to
the diﬀerent R’ substituents of curcumin ligands (Scheme 1).
The IR spectra of 1–4 show the typical ν(CvO, CvC) bands of
curc and bdcurc at lower wavenumbers than the corresponding
bands in the free ligands as a consequence of coordination
through both the carbonyl arms to the metal. In the far-IR
region, several absorptions were observed in the range 482–445
and 252–242 cm−1. These may be assigned to ν(M–O) and
ν(M–Cl) stretches, respectively.42
The NMR spectra of 1–4 corroborate the expected structures
containing the bidentate curcumin and bisdemethoxy-
curcumin ligands. For example, a doublet is observed in the
13C{1H}43 NMR spectra of the rhodium derivatives 1 and 2
around δ 95 ( J (103Rh–13C) ≈ 6.9 Hz), whereas in the spectra of
iridium derivatives 3 and 4 a singlet is observed. The electro-
spray ionisation (ESI) mass spectra of 1–4 display peaks corres-
ponding to the species [Cp*M(curc/bdcurc)]+, in which the
chloride ligand has dissociated.
The chloride ligand in 1–4 is readily replaced by the water-
soluble phosphine 1,3,5-triaza-7-phosphaadamantane (PTA),
by treatment of the complexes with AgSO3CF3 in methanol
containing PTA, aﬀording [Cp*M(curc/bdcurc)(PTA)][SO3CF3]
(M = Rh 5 and 6 and M = Ir 7 and 8), as depicted in Scheme 2.
The substitution of the chloride ligand by PTA and the for-
mation of an ionic compound were confirmed by the dis-
appearance of the ν(M–Cl) band in the IR spectra of 5–8.
Moreover, a characteristic absorption pattern in the region
1000–1200 cm−1, indicative of a non-coordinated O3SCF3
−
anion, has also been observed.44 The 1H NMR spectra of 5–8
in CD3CN display the expected signals due to the coordinated
Cp*, curc or bdcurc and PTA ligands. The resonances due to
the PTA are observed at a lower field with respect to those of
uncoordinated PTA, thus confirming coordination to the metal
center.45
The 31P NMR spectra of rhodium complexes 5 and 6 in
CD3CN display a doublet centered at ca. −34 ppm with a 1JP–Rh
value of ca. 151 Hz, and the iridium derivatives 7 and 8 com-
prise a single resonance at −56 ppm, in a range typical of
related compounds.46,47
The ESI mass spectra of 5–8 in acetonitrile show two main
peak envelopes, that of highest relative intensity corresponding
to the fragment [Cp*M(curc/bdcurc)]+, upon dissociation of
PTA, the other corresponding to the intact species [Cp*M(curc/
bdcurc)(PTA)]+.
Complex 5 in water–DMSO (80–20%) solution is stable, its
31P NMR spectra remaining unchanged after 96 h. The stability
of 5 was also determined under pseudo-pharmacological con-
ditions in 5 mM NaCl solution (being a model for the low
intracellular chloride concentration in cells) and in 100 mM
NaCl solution (approximating to the higher chloride levels in
blood). Solutions of the complexes (c = 2.0 mM) in aqueous
NaCl (c = 5 mM or 100 mM in D2O containing 20% of [D6]-
DMSO) were prepared and maintained at 37 °C for 7 days. The
decomposition of the complexes was monitored by 1H and 31P
NMR spectroscopy.
The 31P{1H} spectrum of 5 displays a doublet at −36.0 ppm
( JPRh = 155 Hz), corresponding to the starting species, [Cp*Rh-
(curc)(PTA)]+ (RhA) (Scheme 3 and Fig. 1).Scheme 1 Synthesis of 1–4.
Scheme 2 Synthesis of 5–8.
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After 1 day, signals indicative of two new species are
observed in both 5 and 100 mM aqueous NaCl solutions. The
first doublet in the range −35.7/−36.0 ppm ( JPRh = 147 Hz)
corresponds to the [Cp*Rh(PTA)2Cl]
+ (RhB) species, previously
reported by Macchioni and co-workers,48 arising from the
release of the curc ligand and its replacement with a chloride
and a second PTA from another [Cp*Rh(curc)(PTA)]+ species,
which in turn likely aﬀords a third neutral species of the
formula [Cp*Rh(curc)Cl] (RhC). The second doublet in the
range −37.3/−37.4 ppm ( JPRh = 134 Hz) corresponds to the
[Cp*Rh(PTA)Cl2] (RhD) species.
48
After 96 h an excess of PTA was added and, immediately,
the resonance of [Cp*Rh(PTA)Cl2] (RhD) disappeared.
Whereas, the intensity of [Cp*Rh(PTA)2Cl]
+ (RhB) increased
and the resonances of [Cp*Rh(curc)(PTA)]+ (RhA) reappeared,
together with a new signal due to [Cp*Rh(PTA)3]
+2 ( JPRh =
120 Hz).48
The 31P NMR spectrum of the iridium compound 7 in
water–DMSO (80–20%) solution showed immediately the
formation of the hydrolysis products [Cp*IrCl2(PTA)] (IrC:
−63.8 ppm) and [Cp*IrCl(OD2)(PTA)]+ (IrB: −65.7 ppm), in
equilibrium with the starting species [Cp*Ir(curc)(PTA)]+ (IrA:
−54.0 ppm). The nature of [Cp*IrCl2(PTA)] has been confirmed
by adding an excess of NaCl (Fig. 2b), whereas the [Cp*IrCl-
(OD2)(PTA)]
+ species has been hypothesized on the basis of a
previous work by Peruzzini.47
The diﬀerence in stability of iridium complexes with
respect to rhodium analogues has been previously observed
for complexes with other ligands such as poly(pyrazolyl)-
borates.49,50
The 31P NMR spectra of 5 in D2O containing 20% DMSO
were recorded at diﬀerent pD values to determine the pKa
value of the coordinated PTA ligand. The chemical shift was
plotted against pD (Fig. 3) and the curve fitted using the Hen-
derson–Hasselbalch equation to give a pKa of 3.36 ± 0.02 (0.44
is subtracted to account for the diﬀerence between the pH and
pD).51
The solid-state structures of 5, 6 and 8 were established by
X-ray crystallography (see the Experimental section). Their
structures are shown in Fig. 4 and relevant bond distances and
angles are given in the caption. The three metal complexes
Scheme 3 Decomposition of 5 (RhA) into [Cp*Rh(PTA)2Cl]
+ (RhB),
[Cp*Rh(curc)Cl] (RhC), [Cp*Rh(PTA)Cl2] (RhD) and into curc, under
pseudo-pharmacological conditions.
Fig. 1 31P NMR spectra of 5 in 5 mM (left) and in 100 mM (right)
aqueous NaCl solution.
Fig. 2 (a) 31P NMR chemical shifts for 7 in D2O–DMSO and (b) after
addition of excess NaCl.
Fig. 3 A plot of the 31P NMR chemical shift (δ) versus pD for 5.
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display the standard piano-stool geometry. Ligands show an
almost planar geometry (the angles between the aromatic
rings being 1.3°, 4.6° and 4.0° for compounds 5, 6 and 8,
respectively), with a small twist around the central backbone
(the calculated dihedral angles for the –CvC(vO)–Cv moi-
eties varies from 1.7° in 5 to 8° in 8 to 8.8° in 6). The bond dis-
tances and angles around the metal centers (see the caption to
Fig. 4) fall in the range of values found in the literature for
similar compounds.19 Strong intermolecular hydrogen bonds
are observed between the ligands and the anions (CF3SO3
−)
[O⋯O, 2.716(2) Å, <OHO, 156(3)° in 5; O⋯O, 2.716(4) Å,
<OHO, 167° in 6; O⋯O, 2.706(7) Å, <OHO, 167° in 8] and
between the ligands and the coordinated PTA of neighboring
complexes [O⋯N, 2.810(2) Å, <OHN, 155(3)° in 5; O⋯N,
2.760(4) Å, <OHN, 163° in 6; O⋯N, 2.744(7) Å, <OHN, 163° in
8]. Additional intramolecular OH⋯O interactions are observed
in the crystal of 5.
The antiproliferative eﬀects of 1–8 were investigated in two
human ovarian cancer cell lines, A2780 and the cisplatin resist-
ant A2780cisR cell line, as well as in non-tumorigenic human
embryonic kidney (HEK293) cells. IC50 values for compounds
1–8 were determined after a 72 hour exposure period using the
MTT assay (Table 1 and the Experimental section).
All the complexes were cytotoxic at moderate micromolar
concentrations against both cancer cell lines with IC50 values
in the 12–23 μM range for A2780 cells and in the 12–40 μM
range for A2780cisR cells, indicating a lack of cross-resistance.
In HEK293 cells comparable IC50 values were obtained
(14–32 μM) suggesting a lack of cancer cell selectivity.
Previously reported Rh(III) Cp* complexes containing maltol
or allomaltol as O^O-chelating ligands were all inactive toward
A549, CH1 and SW480 cell lines,52 whereas the lapachol
complex shows good activity and selectivity toward the CH1
ovarian carcinoma cell line.53 A cyclometalated rhodium(III)
complex shows lower54 or comparable IC50 values toward
A2780 cells.39,55 Ir(III) Cp* complexes of the formula [(η5-Cp*)Ir-
(L^L′)Cl]0/+ containing N^N-(phenanthroline, 2,2′-bipyridine,
ethylenediamine) and N^O-(picolinate) chelating ligands, are
inactive on A2780 cells with IC50 values >100 μM,31,33 even
with modified Cp*-type ligands.31,56 However, varying the
chelating ligand32,40,57–59 can lead to compounds with IC50
values considerably higher than cisplatin.
Cytotoxicity data for the A2780 cell line are comparable
with the IC50 value obtained for [(p-cymene)Ru(curc)Cl] in the
HEK293 cell line, however, the rhodium(III) and iridium(III)
complexes are 20–60 times less active than their corresponding
ruthenium(II) analogues in the ovarian cancer cell lines.
The rhodium(III) and iridium(III) complexes with chloride
1–4 or PTA 5–8 co-ligands exhibit similar biological activities.
Fig. 4 Molecular structures of 5 (top), 6 (middle) and 8 (bottom). The
counter-anion has been omitted for clarity. Bond distances (Å) and
angles (°): [5] Rh1–O1, 2.107(1); Rh1–O2, 2.091(1); Rh1–P1, 2.314(1); Rh1-
η5(centroid), 1.802(1). [6] Rh1–O1, 2.109(2); Rh1–O2, 2.089(2); Rh1–P1,
2.313(1); Rh1-η5(centroid), 1.808(2). [8] Ir1–O1, 2.117(4); Ir1–O2, 2.101(4);
Ir1–P1, 2.299(2), Ir1-η5(centroid), 1.810(3).
Table 1 Cytotoxicity of 1–8 following incubation for 72 h on human
ovarian carcinoma A2780 and A2780R (cisplatin-resistant) and non-
tumorigenic human embryonic kidney HEK293 cell lines
Compound
A2780
(IC50, μM)
A2780cisR
(IC50, μM)
HEK293
(IC50, μM)
curcH 4.0 ± 0.1 3.2 ± 0.2 1.1 ± 0.1
bdcurcH 4.6 ± 0.1 4.6 ± 0.2 2.2 ± 0.1
1 14.9 ± 2.1 12.3 ± 0.3 13.7 ± 0.3
2 20.0 ± 2.0 18.1 ± 0.2 31.8 ± 0.2
3 23.2 ± 0.8 14.1 ± 2.5 16.3 ± 0.7
4 20.7 ± 5.6 23.6 ± 2.3 26.1 ± 2.9
5 12.5 ± 0.5 16.0 ± 3.0 17.2 ± 4.8
6 14.7 ± 2.2 17.7 ± 0.2 19.0 ± 4.0
7 23.2 ± 2.3 39.4 ± 9.4 29.4 ± 3.9
8 21.0 ± 1.0 33.3 ± 3.6 15.6 ± 1.4
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This behaviour contrasts to that of the related ruthenium(II)
complexes, in which the activity/selectivity of the PTA-contain-
ing complexes was superior to the chloride-based complexes.22
However, in keeping with the ruthenium(II) complexes, the
nature of the curcuminoid ligand employed, i.e. curcumin and
bisdemethoxycurcumin, plays little discernible role. It is not
unreasonable to assume that following dissociation of the cur-
cuminoid ligand the rhodium(III)/iridium(III) complexes interact
with diﬀerent biological targets compared to the arene ruthe-
nium(II) derivatives, implying a diﬀerent mechanism of action.
Conclusions
Compared to platinum- or ruthenium-based anticancer agents,
the study of the medicinal properties of rhodium and iridium
complexes is poorly developed. Here, we described a series of
novel pentamethylcyclopentadienyl rhodium(III) and iridium(III)
complexes with curcumin or bisdemethoxycurcumin co-
ligands and a chloride or PTA ligand, these complexes being
closely related to the previously studied arene ruthenium(II)
complexes.24 Unlike related ruthenium(II) complexes with a
PTA ligand, which display 100 times higher cytotoxicity
towards cancer cells versus healthy cells, the compounds
reported here are moderately cytotoxic to both human ovarian
cancer cells and non-tumorigenic human embryonic kidney
cells. Since it has been shown that all these compounds are
able to release their curcuminoid ligands under physiological-
like conditions it would suggest that the diﬀerences in activity
between the pentamethylcyclopentadienyl M(III) (M = Rh/Ir)
and arene ruthenium(II) compounds originate from the
diﬀerent metal fragments, which are known to have diﬀerent
binding preferences for certain biological targets.60
Experimental section
General procedures
The dimers [Cp*MCl2]2 (M = Rh or Ir) were purchased from
Aldrich. Curcumin and bisdemethoxycurcumin were pur-
chased from TCI Europe and were used as received. All other
materials were obtained from commercial sources and were
used as received. IR spectra were recorded from 4000 to
30 cm−1 on a Perkin-Elmer Frontier Spectrometer FT-IR/FIR
instrument. 1H and 13C NMR spectra were recorded on a 400
Mercury Plus Varian instrument operating at room tempera-
ture (400 MHz for 1H and 100 MHz for 13C) relative to TMS.
Positive and negative ion electrospray ionization mass spectra
(ESI-MS) were obtained on a Series 1100 MSI detector HP
spectrometer using methanol as the mobile phase. Solutions
(3 mg mL−1) for analysis were prepared using reagent-grade
methanol. Masses and intensities were compared to those cal-
culated using IsoPro Isotopic Abundance Simulator, version
2.1.28. Melting points are uncorrected and were recorded on a
STMP3 Stuart scientific instrument and on a capillary appar-
atus. Samples for microanalysis were dried in vacuo to constant
weight (20 °C, ca. 0.1 Torr) and analysed on a Fisons Instru-
ments 1108 CHNS-O elemental analyzer.
Synthesis of complexes 1–8
[Cp*Rh(curc)Cl] (1). Curcumin (curc, 184.2 mg, 0.5 mmol)
was dissolved in methanol (20 mL) and KOH (28.05 mg,
0.5 mmol) was added. The mixture was stirred for 1 h at room
temperature and then [Cp*RhCl2]2 (154.52 mg, 0.25 mmol)
was added. The mixture was stirred for 24 h at room tempera-
ture and an orange precipitate formed which was filtered oﬀ
and washed with 5 mL of diethyl ether (278.82 mg, 0.43 mmol,
yield 87%). The residue was concentrated to ca. 2 mL and
stored at 4 °C. Red crystals were slowly aﬀorded within 2 days.
1 is soluble in acetone, acetonitrile, chlorinated solvents,
DMSO and slightly soluble in alcohols. M.p. 264–265 °C. Anal.
Calcd for C31H34ClO6Rh: C, 58.09; H, 5.35. Found: C, 58.00;
H, 5.26. IR (cm−1): 3563 w, 3157 m, 1622 m, 1590 m ν(CvC),
1505 s, 472 m, 454 w, 242 s ν(Rh–Cl). 1H NMR (CDCl3, 293 K):
δ, 1.69 (s, 15H, CH3Cp*), 3.94 (s, 6H, OCH3 of curc), 5.78 (s, 1H,
C(1)H of curc), 6.51 (d, 2H, C(3, 3′)H of curc, 3Jtrans = 16 Hz),
6.90 (d, 2H, C(9, 9′)H of curc, 3JaromH–H = 9 Hz), 7.05 (m, 4H,
C(6, 6′)H and C(10, 10′)H of curc), 7.57 (d, 2H, C(4, 4′)H of
curc, 3Jtrans = 16 Hz).
13C NMR (CDCl3, 293 K): δ, 8.8 (s,
CH3Cp*), 56.1 (s, OCH3 of curc), 94.7 (d, CCp*, J (
103Rh–13C) =
6.9 Hz), 102.2 (s, C(1) of curc), 109.4 (s, C(6, 6′) of curc), 114.8
(s, C(9, 9′) of curc), 122.5 (s, C(10, 10′) of curc), 126.7 (s, C(5, 5′)
of curc), 128.8 (s, C(3, 3′) of curc), 138.4 (s, C(4, 4′) of curc),
146.8 (s, C(7, 7′) of curc), 147.2 (s, C(8, 8′) of curc), 178.7 (s,
C(2, 2′)vO of curc). ESI-MS (+) CH3OH (m/z, relative intensity
%): 605 [100] [Cp*Rh(curc)]+.
[Cp*Rh(bdcurc)Cl] (2). Compound 2 was prepared following
a procedure similar to that reported for 1 by using bdcurc
(270.12 mg, 0.46 mmol, yield 93%). 2 is soluble in acetone,
acetonitrile, DMSO and slightly soluble in alcohols. M.p.
235–236 °C. Anal. Calcd for C29H30ClO4Rh: C, 59.96; H, 5.21.
Found: C, 59.84; H, 5.16. IR (cm−1): 3165 br, 1618 sh, 1599 m
ν(CvC), 1492 s, 478 m, 450 w, 244 s ν(Rh–Cl). 1H NMR
(CD3CN, 293 K): δ, 1.63 (s, 15H, CH3Cp*), 5.94 (s, 1H, C(1)H of
bdcurc), 6.65 (d, 2H, C(3, 3′)H of bdcurc, 3Jtrans = 16 Hz), 6.88
(m, 4H, C(7, 7′)H and C(9, 9′)H of bdcurc), 7.46 (s, 2H, OH of
bdcurc), 7.55 (m, 4H, C(6, 6′)H and C(10, 10′)H of bdcurc), 7.62
(d, 2H, C(4, 4′)H of curc, 3Jtrans = 16 Hz).
13C NMR (CD3CN,
293 K): δ, 9.4 (s, CH3Cp*), 95.5 (d, CCp*, J (
103Rh–13C) = 7.0 Hz),
102.3 (s, C(1) of bdcurc), 116.8 (s, C(7, 7′) and C(9, 9′) of
bdcurc), 122.4 (s, C(6, 6′ and (s, C(10, 10′) of bdcurc), 126.7 (s,
C(5, 5′) of bdcurc), 131.2 (s, C(4, 4′) of bdcurc), 141.1 (s, C(3, 3′)
of bdcurc), 146.8 (s, C(8, 8′) of bdcurc), 178.7 (s, C(2, 2′)vO of
bdcurc). ESI-MS (+) CH3CN (m/z, relative intensity %): 545
[100] [Cp*Rh(bdcurc)]+.
[Cp*Ir(curc)Cl] (3). Compound 3 was prepared following a
procedure similar to that reported for 1 by using [Cp*IrCl2]2
(284.8 mg, 0.39 mmol, yield 78%). 3 is soluble in acetone,
acetonitrile, chlorinated solvents, DMSO and slightly soluble
in alcohols. M.p. 210–212 °C. Anal. Calcd for C31H34ClO6Ir:
C, 50.99; H, 4.69. Found: C, 50.74; H, 4.62. IR (cm−1): 3544 w,
3270 m, 1621 m, 1586 m ν(CvC), 1504 s, 474 m, 461 w, 245 s
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ν(Ir–Cl). 1H NMR (CDCl3, 293 K): δ, 1.66 (s, 15H, CH3Cp*), 3.93
(s, 6H, OCH3 of curc), 5.50 (s, 1H, C(1)H of curc), 6.45 (d, 2H,
C(3, 3′)H of curc, 3Jtrans = 16 Hz), 6.89 (d, 2H, C(9, 9′)H of curc,
3JaromH–H = 8 Hz), 7.05 (m, 4H, C(6, 6′)H and C(10, 10′)H of
curc), 7.55 (d, 2H, C(4, 4′)H of curc, 3Jtrans = 16 Hz).
13C NMR
(CDCl3, 293 K): δ, 9.0 (s, CH3Cp*), 56.2 (s, OCH3 of curc), 83.8
(s, CCp*), 103.3 (s, C(1) of curc), 109.3 (s, C(6, 6′) of curc), 114.9
(s, C(9, 9′) of curc), 122.5 (s, C(10, 10′) of curc), 126.3 (s, C(5, 5′)
of curc), 128.9 (s, C(3, 3′) of curc), 138.3 (s, C(4, 4′) of curc),
147.0 (s, C(7, 7′) of curc), 147.2 (s, C(8, 8′) of curc), 176.5 (s,
C(2, 2′)vO of curc). ESI-MS (+) CH3OH (m/z, relative intensity
%): 695 [100] [Cp*Ir(curc)]+.
[Cp*Ir(bdcurc)Cl] (4). Compound 4 was prepared following
a procedure similar to that reported for 2 by using [Cp*IrCl2]2
(298.25 mg, 0.44 mmol, yield 89%). 4 is soluble in alcohols,
acetone, acetonitrile, DMSO and slightly soluble in chlorinated
solvents. M.p. 230–232 °C. Anal. Calcd for C29H30ClIrO4:
C, 51.97; H, 4.51. Found: C, 51.84; H, 4.48. IR (cm−1): 3214 w,
1621 sh, 1598 m ν(CvC), 1493 s, 1269 s, 1158 s, 482 m, 445 w,
252 s ν(Ir–Cl). 1H NMR (CD3CN, 293 K): δ, 1.63 (s, 15H,
CH3Cp*), 5.51 (s, 1H, C(1)H of bdcurc), 6.57 (d, 2H, C(3, 3′)H of
bdcurc, 3Jtrans = 16 Hz), 6.87 (m, 4H, C(7, 7′)H and C(9, 9′)H of
bdcurc), 7.37 (s, 2H, OH of bdcurc), 7.55 (m, 4H, C(6, 6′)H and
C(10, 10′)H of bdcurc), 7.61 (m, 2H, C(4, 4′)H of bdcurc). 13C
NMR (CD3CN, 293 K): δ, 8.9 (s, CH3Cp*), 92.7 (s, CCp*), 101.6 (s,
C(1) of bdcurc), 116.6 (s, C(7, 7′) and C(9, 9′) of bdcurc), 121.4
(s, C(6, 6′ and (C(10, 10′) of bdcurc), 126.5 (s, C(5, 5′) of
bdcurc), 131.0 (s, C(4, 4′) of bdcurc), 141.0 (s, C(3, 3′) of
bdcurc), 160.5 (s, C(8, 8′) of bdcurc), 183.8 (s, C(2, 2′)vO of
bdcurc). ESI-MS (+) CH3CN (m/z, relative intensity %): 635
[100] [Cp*Ir(bdcurc)]+.
[Cp*Rh(curc)(PTA)][SO3CF3] (5). AgSO3CF3 (64 mg,
0.25 mmol) was added to a solution of 1 (160 mg, 0.25 mmol)
in acetonitrile. The reaction mixture was stirred for 1 h and fil-
tered to remove AgCl. PTA was added and the reaction was
carried out for 24 h at room temperature. The solvent was
removed under reduced pressure and methanol and diethyl
ether (20 mL) was added. The mixture was left at 4 °C until an
orange precipitate formed. The orange crystalline powder was
recovered by filtration and air-dried (154.9 mg, 0.169 mmol,
yield 68%) and it was identified as 5. It is soluble in alcohols,
acetone, acetonitrile, DMSO and slightly soluble in chlorinated
solvents and water. M.p. 253–254 °C. Anal. Calcd for
C38H46F3N3O9PRhS: C, 50.06; H, 5.09; N, 4.61. Found: C, 50.00;
H, 5.01; N, 4.55. IR (cm−1): 3258 w, 2925 w, 1621 sh, 1601 m,
1583 m ν(CvC), 1496 s, 1270 s, 1148 s, 1029 s ν(SO3CF3),
570 m ν(Rh–P), 472 m, 454 w, 421 w ν(Rh–P). 1H NMR (CD3CN,
293 K): δ, 1.68 (d, 15H, CH3Cp*, JHP = 3.4 Hz), 3.94 (s, 6H, OCH3
of curc), 4.17 (s, 6H, NCH2N, PTA), 4.49 (s, 6H, PCH2N, PTA),
5.65 (s, 1H, C(1)H of curc), 6.76 (d, 2H, C(3, 3′)H of curc,
3Jtrans = 16 Hz), 6.89 (d, 2H, C(9, 9′)H of curc,
3JaromH–H = 8 Hz),
6.95 (sbr, 2H, OH of curc), 7.16 (dd, 2H, C(10, 10′)H of curc,
3JaromH–H = 8 Hz), 7.28 (s, 2H, C(6, 6′)H of curc), 7.61 (d, 2H,
C(4, 4′)H of curc 3Jtrans = 16 Hz).
13C NMR (CD3CN, 293 K): δ,
7.2 (s, CH3Cp*), 47.8 (d, NCH2P, PTA, JCP = 11.1 Hz), 54.8 (s,
OCH3 of curc), 71.3 (d, NCH2N, PTA, JCP = 6.9 Hz), 97.9 (d,
CCp*, J (
103Rh–13C) = 6.8 Hz), 102.7 (s, C(1) of curc), 109.5 (s,
C(6, 6′) of curc), 114.0 (s, C(9, 9′) of curc), 121.8 (s, C(10, 10′) of
curc), 124.4 (s, C(5, 5′) of curc), 126.9 (s, C(3, 3′) of curc), 139.0
(s, C(4, 4′) of curc), 146.7 (s, C(7, 7′) of curc), 147.4 (s, C(8, 8′)
of curc), 179.2 (s, C(2, 2′)vO of curc). 31P NMR (CD3CN,
293 K): δ = −34.9 (d, JPRh = 151 Hz, PTA). ESI-MS (+) CH3CN
(m/z, relative intensity %): 605 [100] [Cp*Rh(curc)]+, 762 [10]
[Cp*Rh(curc)(PTA)]+.
[(Cp*)Rh(bdcurc)(PTA)][SO3CF3] (6). Compound 6 was pre-
pared following a procedure similar to that reported for 5 by
using precursor 2 (129.8 mg, 0.15 mmol, yield 61%). 6 is
soluble in alcohols, acetone, acetonitrile, DMSO, chlorinated
solvents and slightly soluble in water. M.p. 237–239 °C. Anal.
Calcd for C36H42F3N3O7PRhS: C, 50.77; H, 4.97; N, 4.93.
Found: C, 50.68; H, 4.86; N, 4.82. IR (cm−1): 3157 br, 1617 sh,
1602 m, 1588 m ν(CvC), 1493 s, 1277 s, 1160 s, 1025 s
ν(SO3CF3), 580 m, 571 m ν(Rh–P), 476 s, 450 w, 346 w ν(Rh–P).
1H NMR (CD3CN, 293 K): δ, 1.67 (d, 15H, CH3Cp*, JHP = 3.4 Hz),
4.16 (s, 6H, NCH2N, PTA), 4.48 (s, 6H, PCH2N, PTA), 5.65 (s,
1H, C(1)H of bdcurc), 6.71 (d, 2H, C(3, 3′)H of bdcurc, 3Jtrans =
16 Hz), 6.88 (m, 4H, C(7, 7′)H and C(9, 9′)H of bdcurc), 7.40 (s,
2H, OH of bdcurc), 7.55 (m, 4H, C(6, 6′)H and C(10, 10′)H of
bdcurc), 7.62 (d, 2H, C(4, 4′)H of bdcurc, 3Jtrans = 16 Hz).
13C
NMR (CD3CN, 293 K): δ, 8.5 (s, CH3Cp*), 48.8 (d, NCH2P, PTA,
JCP = 9.9 Hz), 72.5 (d, NCH2N, PTA, JCP = 11.1 Hz), 91.6 (s, CCp*)
(d, CCp*, J (
103Rh–13C) = 7.0 Hz), 104.0 (s, C(1) of bdcurc), 116.1
(s, C(7, 7′) and C(9, 9′) of bdcurc), 125.4 (s, C(6, 6′) and C(10,
10′) of bdcurc), 127.6 (s, C(5, 5′) of bdcurc), 130.2 (s, C(4, 4′) of
bdcurc), 139.9 (s, C(3, 3′) of bdcurc), 159.8 (s, C(8, 8′) of
bdcurc), 178.4 (s, C(2, 2′)vO of bdcurc). 31P NMR (CD3CN,
293 K): δ = −34.9 (d, JPRh = 151 Hz, PTA). ESI-MS (+) CH3CN
(m/z, relative intensity %): 545 [100] [Cp*Rh(bdcurc)]+, 702 [10]
[Cp*Rh(bdcurc)(PTA)]+.
[Cp*Ir(curc)(PTA)][SO3CF3] (7). Compound 7 was prepared
following a procedure similar to that reported for 5 by using
precursor 3 (157.66 mg, 0.15 mmol, yield 63%). 7 is soluble in
alcohols, acetone, acetonitrile, DMSO and slightly soluble in
chlorinated solvents and water. M.p. 227–229 °C. Anal. Calcd
for C38H46F3IrN3O9PS: C, 45.59; H, 4.63; N, 4.20. Found: C,
45.50; H, 4.57; N, 4.14. IR (cm−1): 2924 br, 1613 sh, 1599 m,
1584 m ν(CvC), 1493 s, 1270 s, 1149 s, 1028 s ν(SO3CF3),
575 m ν(Ir–P), 472 m, 453 w, 390 w ν(Ir–P). 1H NMR (CD3CN,
293 K): δ, 1.70 (d, 15H, CH3Cp*, JHP = 1.9 Hz). 3.94 (s, 6H, OCH3
of curc), 4.16 (s, 6H, NCH2N, PTA), 4.48 (m, 6H, PCH2N, PTA),
5.71 (s, 1H, C(1)H of curc), 6.69 (d, 2H, C(3, 3′)H of curc,
3Jtrans = 16 Hz), 6.89 (d, 2H, C(9, 9′)H of curc,
3JaromH–H =
8 Hz)), 7.04 (s, 2H, OH of curc), 7.18 (dd, 2H, C(10, 10′)H of
curc, 3JaromH–H = 8 Hz), 7.30 (s, 2H, C(6, 6′)H of curc), 7.63 (d,
2H, C(4, 4′)H of curc, 3Jtrans = 16 Hz).
13C NMR (CDCl3, 293 K):
δ, 9.4 (s, CH3Cp*), 49.4 (d, PCH2N, PTA, JCP = 18.8 Hz), 57.1 (s,
OCH3 of curc), 73.6 (d, NCH2N, PTA, JCP = 7.1 Hz), 93.5 (s,
CCp*), 105.9 (s, C(1) of curc), 111.7 (C(6, 6′) of curc), 116.4 (C(9,
9′) of curc), 124.1 (C(10, 10′) of curc), 125.7 (C(5, 5′) of curc),
129.2 (C(3, 3′) of curc), 141.4 (C(4, 4′) of curc), 149.0 (C(7, 7′) of
curc), 149.7 (C(8, 8′) of curc), 179.5 (C(2, 2′)vO of curc).
31P NMR (CD3CN, 293 K): δ = −56.1 (s, PTA). ESI-MS (+) CH3CN
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(m/z, relative intensity %): 695.2 [100] [Cp*Ir(curc)]+, 852 [30]
[Cp*Ir(curc)(PTA)]+.
[Cp*Ir(bdcurc)(PTA)][SO3CF3] (8). Compound 8 was pre-
pared following a procedure similar to that reported for 5 by
using precursor 4 (152.91 mg, 0.16 mmol, yield 65%). 8 is
soluble in alcohols, acetone, acetonitrile and DMSO. M.p.
249–251 °C. Anal. Calcd for C36H42F3IrN3O7PS: C, 45.95; H,
4.50; N, 4.47. Found: C, 45.83; H, 4.44; N, 4.41. IR (cm−1):
3155br, 1615 sh, 1602 m, 1586 m ν(CvC), 1491 s, 1278 s, 1160
s, 1025 s ν(SO3CF3), 600 m, 577 m ν(Ir–P), 482 s, 456 w, 346 w
ν(Ir–P). 1H NMR (CD3CN, 293 K): δ, 1.69 (d, 15H, CH3Cp*, JHP =
2.0 Hz), 4.16 (s, 6H, NCH2N, pta), 4.48 (m, 6H, PCH2N, pta),
5.71 (s, 1H, C(1)H of bdcurc), 6.63 (d, 2H, C(3, 3′)H of bdcurc,
3Jtrans = 16 Hz), 6.88 (m, 4H, C(7, 7′)H and C(9, 9′)H of bdcurc),
7.44 (s, 2H, OH of bdcurc), 7.57 (m, 4H, C(6, 6′)H and C(10,
10′)H of bdcurc), 7.64 (d, 2H, C(4, 4′)H of bdcurc, 3Jtrans = 16
Hz). 13C NMR (CD3CN, 293 K): δ, 8.5 (s, CH3Cp*), 48.1 (d,
PCH2N, PTA, JCP = 18.4 Hz), 72.5 (d, NCH2N, PTA, JCP = 7.7 Hz),
92.4 (s, CCp*), 105.0 (s, C(1) of bdcurc), 116.2 (s, C(7, 7′) and
C(9, 9′) of bdcurc), 124.4 (s, C(6, 6′) and C(10, 10′) of bdcurc),
127.7 (s, C(5, 5′) of bdcurc), 130.2 (s, C(4, 4′) of bdcurc), 140.1
(s, C(3, 3′) of bdcurc), 159.2 (s, C(8, 8′) of bdcurc), 178.4 (s, C(2,
2′)vO of bdcurc). 31P NMR (CD3CN, 293 K): δ = −56.3 (s, PTA).
ESI-MS (+) CH3CN (m/z, relative intensity %): 635 [100] [Cp*Ir-
(bdcurc)]+, 792 [20] [Cp*Ir(bdcurc)(PTA)]+.
X-ray crystal structure determination
Diﬀraction data were measured at low temperature [100(2) K]
using Mo Kα radiation on a Bruker APEX II CCD diﬀractometer
equipped with a kappa geometry goniometer. The datasets
were reduced by using EvalCCD61 and then corrected for
absorption.62 The solutions and refinements were performed
by using SHELX.63 The crystal structures were refined using
full-matrix least-squares based on F2 with all non-hydrogen
atoms anisotropically defined. Hydrogen atoms were placed in
calculated positions by means of the “riding” model. Disorder
problems dealing with CF3SO3
− were encountered during the
last stages of refinement and treated by using the split model
(SADI and SIMU cards were applied to retain a reasonable geo-
metry and acceptable ADP).
Cell culture and inhibition of cell growth
The human A2780 and A2780cisR ovarian carcinoma and HEK
(human embryonic kidney) cells were obtained from the
European Collection of Cell Cultures (Salisbury, U.K.).
A2780 and A2780cisR cells were grown routinely in
RPMI-1640 medium, while HEK cells were grown in DMEM
medium, with 10% fetal bovine serum (FBS) and 1% anti-
biotics at 37 °C and 5% CO2. Cytotoxicity was determined
using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide). The cells were seeded in
96-well plates as monolayers with 100 μL of cell suspension
(approximately 5000 cells) per well and pre-incubated for 24 h
in a medium supplemented with 10% FBS. Compounds were
prepared as DMSO solutions and then dissolved in the culture
medium and serially diluted to the appropriate concentration,
to give a final DMSO concentration of 0.5%. 100 μL of the drug
solution was added to each well, and the plates were incubated
for another 72 h. Subsequently, MTT (5 mg mL−1 solution) was
added to the cells and the plates were incubated for a further
2 h. The culture medium was aspirated, and the purple forma-
zan crystals formed by the mitochondrial dehydrogenase
activity of vital cells were dissolved in DMSO. The optical
density, directly proportional to the number of surviving cells,
was quantified at 590 nm using a multiwell plate reader, and
the fraction of surviving cells was calculated from the absor-
bance of untreated control cells. Evaluation is based on means
from at least two independent experiments, each comprising
triplicates per concentration level.
Determination of pKa values
The pH values of NMR samples in D2O were measured at
298 K, directly in the NMR tube, using a 713 pH meter
(Metrohm) equipped with an electrode calibrated with buﬀer
solutions at pH values of 4, 7, and 9. The pH values were
adjusted with dilute HNO3 and NaOH. The pH titration curves
were fitted to the Henderson–Hasselbalch equation using the
program Matlab (MathWorks Software) with the assumption
that the observed chemical shifts are weighted averages
according to the populations of the protonated and deproto-
nated species. The resonance frequencies change smoothly
with pH between the chemical shifts of the charged form HA+,
stable in acidic solution, and those of the neutral, deproto-
nated form A, which is present at a high pH. At any pH, the
observed chemical shift is a weighted average (δav) of the two
extreme values δ(HA+) and δ(A):
δav ¼ δðHA
þÞ HAþ½  þ δðAÞ A½ 
HAþ½  þ A½ 
The midpoint of the titration occurs when the concen-
trations of the acid and its conjugate base are equal: [HA+] =
[A], that is, when the pH equals the pKa of the compound. The
pH at the midpoint of the curve is corrected by subtracting
0.44 to the pD values since the measurements were made in
D2O.
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